olfactory receptor family 7 subfamily E member 2 pseudogeneGenealiases: OR11-6 · OR7E143P · OR7E51P · OR7E52P · OR7F2P · OST245
Q-omics provides the consensus-scored OR7E2P profile across patient tissues and cancer cell-line models. OR7E2P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, OR7E2P is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, OR7E2P RNA expression shows 16,318 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LUAD, KIRC, and PDAC as cancer lineages where OR7E2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7E2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7E2P survival associations across molecular data types. OR7E2P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7E2P RNA expression–survival associations across cancer types. High OR7E2P expression shows unfavorable associations in LUAD, LIHC, THYM and UCEC, but favorable associations in BLCA and KIRP. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for OR7E2P RNA expression.
This table summarizes OR7E2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR7E2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7E2P shows lower tumor expression in LUSC, BRCA and LUAD and higher tumor expression in KIRC, KIRP and COAD. The KIRC box plot shows higher OR7E2P RNA expression in tumor versus normal tissue (log2 FC = +0.105, t-test p < 0.001).
This table shows molecular features associated with OR7E2P in patient tissues and cancer cell lines. In patient samples, OR7E2P shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, OR7E2P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
